Genovis AB
STO:GENO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| SE |
G
|
Genovis AB
STO:GENO
|
1.4B SEK |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.2T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
220B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
157.4B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
80.4T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.3B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
39.4B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
265.1B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.2B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.2B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.4B USD |
Loading...
|
Market Distribution
| Min | -2 025 693.8% |
| 30th Percentile | -1.8% |
| Median | 6% |
| 70th Percentile | 12.5% |
| Max | 10 459.2% |
Other Profitability Ratios
Genovis AB
Glance View
Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Genovis AB is 15.9%, which is below its 3-year median of 25.7%.
Over the last 3 years, Genovis AB’s Operating Margin has decreased from 31.3% to 15.9%. During this period, it reached a low of 13.5% on Dec 31, 2022 and a high of 34.7% on Dec 31, 2023.
